Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 232

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 232
---
iv) amends or modifies certain provisions of the Merger
Agreement in a manner that would reasonably be expected to prevent (A) the Corporate Mergers, taken together, from qualifying as a reorganization within the meaning of Section 368(a) of the Code or (B) the delivery to Clearwater and
Enfusion of the Opinions by their respective Tax Counsels on the Closing Date, but before the Effective Time.

Pursuant to each Support
Agreement, the parties to such Support Agreement will be entitled to an injunction, specific performance of the terms of such Support Agreement and other equitable relief to prevent breaches or threatened breaches of such Support Agreement by any
other party to such Support Agreement. The Support Agreements are governed by Delaware law. The venue for disputes relating to the Support Agreements is the Court of Chancery of the State of Delaware or, if that court does not have subject matter
jurisdiction, the state or federal courts in the State of Delaware.

146

OTHER MATTERS

It is not presently expected that any matters other than those discussed herein will be brought before the Special Meeting. If, however, other
matters properly come before the Special Meeting, it is the intention of the persons named in the enclosed form of proxy to vote the shares they represent as the Enfusion Board may recommend.

147

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information presents the pro forma effects of the acquisition of Enfusion by Clearwater. On January 10, 2025, Clearwater entered into the Merger Agreement with Enfusion, Enfusion OpCo, CWAN Acquirer, Merger Sub, and Merger Sub II. Pursuant to the terms of the Merger Agreement, (i) Merger Sub II will be merged with and into Enfusion OpCo, with Enfusion OpCo surviving the LLC Merger as an indirect subsidiary of Clearwater, (ii) Merger Sub will merge with and into Enfusion, with Enfusion surviving the Merger as a direct, wholly-owned subsidiary of Clearwater, and (iii) subject to the satisfaction of certain conditions set forth in the Merger Agreement prior to the Effective Time, the Surviving Corporation will merge with and into Acquirer, with Acquirer surviving the Second Merger as a direct, wholly-owned subsidiary of Clearwater. See the section titled “The Transactions” for additional information on the effects of the Transactions. Under